Edwards Lifesciences Bid Lower on Earnings Results

Shares of Edwards Lifesciences EW are bid lower in the after-hours following the release of the company's Q2 earnings results. Currently, shares are bid $81.27, at $82.00; they ended the regular session lower by 5.69%, at $82.55. Edwards Lifesciences said that Q2 EPS came in at $0.49 on revenues of $431.2 million; the Street was looking for $0.50 per share on revenues of $425.4 million. Revenues increased 18.1% year over year. "Growth outside the U.S. was particularly strong this quarter, including another impressive quarter for transcatheter heart valves," said Michael A. Mussallem, chairman and CEO. "Our core heart valve and critical care product lines continued to perform well globally. And, we were pleased with the FDA advisory panel's recommendation for approval yesterday, which reinforces our confidence in a 2011 U.S. launch for the Edwards SAPIEN transcatheter heart valve." Edwards Lifesciences Corporation is a global player in products and technologies designed to treat advanced cardiovascular disease.